Xabier Garcia-Albeniz, Ph.D., a research associate at the Harvard School of Public Health in Boston and the study's lead author, many doctors feel comfortable deferring ADT on the basis of their own clinical experience.
"They see patients doing well without therapy," he said. "Now these data support their observations."
"The results show that the timing of ADT doesn't matter," added Joel Nelson, M.D., chair of the department of urology at the University of Pittsburgh School of Medicine, who wasn't involved in the study. "As long as patients aren't symptomatic, it's reasonable to hold off on ADT for as long as possible and spare patients the effects of treatment."
The levels that define biochemical relapse vary depending on whether patients were treated with radical prostatectomywhich should eliminate PSA from the body-or radiation, which can leave functional prostate tissue intact. According to the American Urological Association, PSA levels of 0.2-0.4 ng/mL in blood predict treatment failure after radical prostatectomy, whereas expert radiology guidelines define biochemical relapse as a level of 2 ng/mL or more over the lowest level identified after radiation treatment.
No Difference in Overall Survival
This observational study investigated 2,022 men tracked by a national cancer registry at the University of California, San Francisco. Some started on ADT within 3 months of relapse, whereas others waited at least 2 years, or until cancer symptoms appeared. Garcia-Albeniz reported that 87.2% of the patients who delayed ADT after relapse were still alive 5 years later, compared with 85.1% of those who waited. Moreover, survival rates stayed similar even among a smaller patient group tracked for nearly 10 years.
All the men were treated initially for nodenegative cancers, which are less aggressive than cancers spreading beyond the prostate As to the pushback surrounding funding in the new clinical trials network, Sellers empathized with the challenge Varmus faces, given a flat budget and fixed personnel costs in NCI's intramural program.
"And, when you look at the data, NCI has been very transparent as to where the dollars are going," he said, with a priority on fundamental research. "You never know when a discovery will open up a new paradigm for treatment."
Still, he added, basic science should not be pitted against research that takes these discoveries from the laboratory bench to a patient's bedside.
"We need to be part of the solution, so that constituents are demanding from Congress better funding of biomedical research," Sellers said. "Scientists and doctors get cancers, too, so it benefits us all."
JNCI | News 5 of 8 jnci.oxfordjournals.org N E W S capsule at diagnosis. The results don't surprise Stephen Freedland, M.D., a urological oncologist at Duke University in Durham, N.C. He cites a 1999 study in the Journal of the American Medical Association of rou ghly 300 men with biochemical relapse, which found that the interval between the rise in PSA and clinical metastasis lasted a median of 8 years, with a median of 5 years' additional time remaining until death from metastatic disease.
"The point is that the natural history of recurrent prostate cancer is long and thus there is no need to rush to treat most people," Freedland said.
Nelson concurs and says these data show how clinicians "can exploit the pokey growth rate of most prostate cancers," but he warns that ADT should not be delayed in the minority of men whose PSA levels double faster than every 3 months. Then, he says, metastases can appear within a year and settle in the bones. Once there, they cause excruciating pain and elevate risks for debilitating skeletal problems, such as spinal cord compression. Similarly, experts advise against delaying ADT if relapse occurs within a year after primary treatment, or if patients had been treated initially for high-grade (Gleason score of 8 or more) tumors. Edward Messing, M.D., chair of the Department of Urology at the University of Rochester School of Medicine and Dentistry in Rochester, N.Y., warns that 80% of patients treated with radical prostatectomy for node-positive prostate cancer will experience recurrence. And for these patients, he said, immediate ADT after biochemical relapse is associated with statistically significant improvements in overall survival and lessened pain from metastatic disease. Messing and colleagues published those data in The Lancet in 2006.
But Messing emphasizes that just a fraction of the men with biochemical relapse fall into high-risk categories. According to Freedland's research published in the Journal of the American Medical Association in 2005, only 6% of men had a PSA doubling time of less than 3 months, for instance. Most of the rest have lower-to moderaterisk profiles, and this is the population for whom the new Harvard study is most relevant.
Managing Anxiety
Joseph Domingo-Domenech, M.D., Ph.D., an assistant professor of pathology at the Mount Sinai School of Medicine in New York, says the findings could be useful for patient discussions about how to respond to biochemical relapse. Rising PSA generates a lot of worry among men who thought they were done with treatment. And according to Domingo-Domenech, many want to begin ADT simply to be proactive.
"When you're in clinical practice, you need to know how to manage anxiety," he said. "With the evidence from this study, we can say, 'This treatment will be more toxic than beneficial to you, and there is no harm in waiting.'"
The challenge is that because ADT reliably lowers PSA levels, "you as the doctor look like a hero if you make them go the other way," Nelson added. That can satisfy patients-and lawyers. But even as ADT drops PSA, it ages patients prematurely and increases odds that they will die from another cause.
"If you're the caregiver, your numberone goal is to make sure that your patients don't die from prostate cancer," Nelson said. "So if they die from something else, you've done your job." 
Identifying Cancer Mutations as Therapeutic Targets
By Anna Azvolinsky C ancer therapies are increasingly targeting specific molecular pathways and mutations. Molecular testing to identify a mutation expressed in a tumor is becoming common both in clinical research and to gauge whether a patient is eligible for a Food and Drug Administrationapproved therapy.
These molecular testing efforts have focused on well-defined pathways that drive tumor growth, such as the phosphatidylinositol 3-kinase (PI3K) and the human epidermal growth factor receptor 2 pathways. And yet researchers are just beginning to understand the genes and pathways important for progression of various tumor types.
Although a diagnostic screening test for a single molecular alteration is increasingly becoming common clinical practice, cancer researchers strive to go beyond this method to provide a wider picture of a tumor's molecular landscape.
Importance of Single-Patient Studies
Although treatment with targeted therapies often works well initially, many patients develop resistance after chronic exposure to an agent that inhibits a cancer pathway.
"It is fairly well established that there are two major resistance mechanisms: acquired and adaptive resistance," said Pau Castel, graduate student in the laboratory of José Baselga, M.D., Ph.D., medical oncologist and physician in chief at the Memorial Sloan-Kettering Cancer Center in New York. "[Patients treated with targeted agents who initially respond] tend to acquire adaptive resistance. Tumors are made up of a spectrum of clones and under targeted therapeutic pressure, one
